Research Summary

My research program is focused on imaging cancer using MRI and novel PET tracers. At UCSF, I have developed the gallium-68 DOTA-TOC imaging program for neuroendocrine tumor staging, and am the principle investigator on the FDA IND. I have also successfully brought Ga-68 PSMA imaging to UCSF and am currently drafting the IND submission to allow for the evaluation of the clinical use of this agent. I am interested in using somatostatin receptor and PSMA based PET agents in order to distinguish neuroendocrine prostate cancer from adenocarcinoma. Additionally, I believe that the combination of MR and PET parameters will aid in the staging of cancers. Most straightforward is a study we are carrying out in low risk prostatectomy patients where we are evaluating the use of PET/MRI using Ga-68 PSMA and MR imaging of the primary tumor. In the setting of patients with metastatic disease, PET/MRI will likely have an even more important role, as response to treatment will change uptake of non-FDG tracers in ways that are not immediately clear and intepretation will likely rely on changes in MR imaging parameters such as diffusion weighted imaging (DWI).

Research Funding

  • July 1, 2019 - June 30, 2024 - MELT: Modulation of PSMA Expression for Lutetium Therapy, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA235741
  • March 6, 2017 - February 28, 2022 - Qualification and Harmonization of PET/MRI for Cancer Clinical Trials, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA212148
  • June 1, 2019 - April 30, 2021 - Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA229354
  • July 1, 2019 - June 30, 2024 - MELT: Modulation of PSMA Expression for Lutetium Therapy, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA235741

Education

Duke University, Durham, NC, BA/BS, 6/2001, Biology, Economics
Stanford University, MD, 6/2007 Medicine
Kaiser San Francisco, 6/2008, Internal Medicine
University of California, San Francisco, 6/2012, Diagnostic Radiology Residency
Stanford University, 6/2013, Body MRI/nuclear medicine Fellowship

Honors & Awards

  • 2001
    Summa Cum Laude, Duke University
  • 2001
    Phi Beta Kappa, Duke University
  • 2006
    Trainee Research Prize, Radiological Society of North America
  • 2007
    W. S. Moore Award, Nominee, International Society of Magnetic Resonance in Medicine
  • 2011
    Magnum Cum Laude Merit Award, International Society of Magnetic Resonance in Medicine
  • 2012
    Roentgen Resident/Fellow Research Award, Radiological Society of North America
  • 2012
    Alexander Margulis Society Excellence in Research Award, UCSF
  • 2014
    Wylie J. Dodds Research Award, Society of Abdominal Radiology

Selected Publications

  1. Bucknor MD, Hope T Reply: "Disparities in PET imaging for prostate cancer at a tertiary academic medical center".  View on PubMed
  2. High-specific-activity 131I-MIBG vs 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma.  View on PubMed
  3. Hope TA, Graves CE, Calais J, Ehman E, Johnson GB, Thompson D, Aslam M, Duh QY, Gosnell J, Shen W, Roman S, Sosa JA, Kluijfhout W, Seib CS, Villanueva-Meyer J, Pampaloni MH, Suh I Accuracy of 18F-fluorocholine PET for the detection of parathyroid adenomas: prospective single center study.  View on PubMed
  4. Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, Eiber M, Haberkorn U, Hofman MS, Hope TA, Kumar R, Rowe SP, Schwarzenboeck SM, Fanti S, Herrmann K E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.  View on PubMed
  5. Koontz BF, Hope TA More Answers and More Questions About Radiotherapy for Metastatic Prostate Cancer.  View on PubMed
  6. Hope TA, Calais J PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer.  View on PubMed
  7. Sartor O, Hope TA, Calais J, Fendler WP Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA.  View on PubMed
  8. Murthy V, Sonni I, Jariwala N, Juarez R, Reiter RE, Raman SS, Hope TA The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer.  View on PubMed
  9. Whitman J, Allen IE, Bergsland EK, Suh IA, Hope TA Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis.  View on PubMed
  10. Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, Elashoff D, Nickols NG, Czernin J Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.  View on PubMed
  11. Tranel J, Feng FY, St James ST, Hope TA Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow.  View on PubMed
  12. Hope TA From Compassionate Use to Phase 3 Trial: The Impact of Germany's PSMA-617 Literature.  View on PubMed
  13. Hope TA Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET.  View on PubMed
  14. Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S, Hope TA Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer.  View on PubMed
  15. Lawhn-Heath C, Yom SS, Liu C, Villanueva-Meyer JE, Aslam M, Smith R, Narwal M, Juarez R, Behr SC, Pampaloni MH, Chan JW, Glastonbury CM, Hope TA, Flavell RR Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study.  View on PubMed
  16. Johnson RD, Bath NK, Rinker J, Fong S, St James S, Pampaloni MH, Hope TA Introduction to the D-SPECT for Technologists: Workflow Using a Dedicated Digital Cardiac Camera.  View on PubMed
  17. Bucknor MD, Lichtensztajn DY, Lin TK, Borno HT, Gomez SL, Hope TA Disparities in PET imaging for prostate cancer at a tertiary academic medical center.  View on PubMed
  18. Osborne JR, Hope TA A Conversation Between Joseph Osborne and Thomas Hope.  View on PubMed
  19. Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer.  View on PubMed
  20. Murthy V, Smith RL, Tao DH, Lawhn-Heath CA, Korenchan DE, Larson PEZ, Flavell RR, Hope TA 68Ga-PSMA-11 PET/MRI: determining ideal acquisition times to reduce noise and increase image quality.  View on PubMed

Go to UCSF Profiles, powered by CTSI